News Daily News Most Secondary Prevention Patients Are Eligible for Multiple Drugs Michael O'Riordan January 03, 2020
News Daily News FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl Michael O'Riordan November 14, 2019
News Daily News FDA Approves Dalteparin Sodium as First Anticoagulant For Use in Pediatric VTE Patients Yael L. Maxwell May 16, 2019
News Daily News PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction Michael O'Riordan April 29, 2019
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for January 2019 Caitlin E. Cox January 31, 2019
News Daily News European Regulators Strike Secondary Prevention Claim for Omega-3 Drugs Shelley Wood December 18, 2018
News Daily News FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now Michael O'Riordan November 01, 2018
News Daily News Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond Shelley Wood December 26, 2017
News Daily News PCSK9 Inhibitors: More Data Show Disappointing Approval Rates of Prescriptions by Payers Yael L. Maxwell October 30, 2017
News Features Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond Shelley Wood December 30, 2016